Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens
Authors:
- C Orla MorrisseyCMC Orla Morrissey
- Hannah Yejin KimHKHannah Yejin Kim
- Katherine GarnhamKGKatherine Garnham
- Aiken DaoAiken Dao
- Arunaloke ChakrabartiACArunaloke Chakrabarti
- John R PerfectJohn R Perfect
- Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
- Thomas S HarrisonTHThomas S Harrison
- Felix BongominFelix Bongomin
Open Access
- 27 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (6)
Abstract
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list (FPPL). This systematic review aimed to evaluate the epidemiology and impact of invasive fungal disease due to Mucorales. PubMed and Web of Science were searched to identify studies published between January 1, 2011 and February 23, 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 24 studies were included. Mortality rates of up to 80% were reported. Antifungal susceptibility varied across agents and species, with the minimum inhibitory concentrations lowest for amphotericin B and posaconazole. Diabetes mellitus was a common risk factor, detected in 65%–85% of patients with mucormycosis, particularly in those with rhino-orbital disease (86.9%). Break-through infection was detected in 13.6%–100% on azole or echinocandin antifungal prophylaxis. The reported prevalence rates were variable, with some studies reporting stable rates in the USA of 0.094–0.117/10 000 discharges between 2011 and 2014, whereas others reported an increase in Iran from 16.8% to 24% between 2011 and 2015. Carefully designed global surveillance studies, linking laboratory and clinical data, are required to develop clinical breakpoints to guide antifungal therapy and determine accurate estimates of complications and sequelae, annual incidence, trends, and global distribution. These data will provide robust estimates of disease burden to refine interventions and better inform future FPPL.Keywords
Funding Information
- Ministry of Education and Science
- World Health Organization
This publication has 94 references indexed in Scilit:
- Medical and surgical treatment of rhino-orbital-cerebral mucormycosis in a child with leukemiaAmerican Journal of Ophthalmology Case Reports, 2021
- Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestationsJapanese Journal of Ophthalmology, 2021
- Is Mucormycosis an inevitable complication of Covid-19 in India?The Brazilian Journal of Infectious Diseases, 2021
- Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of LiteratureMycopathologia, 2021
- A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosisInfection, 2020
- Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from ChinaMycopathologia, 2020
- A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in IndiaClinical Microbiology and Infection, 2020
- The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reportsClinical Microbiology and Infection, 2019
- Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)Clinical Microbiology and Infection, 2016
- Gastrointestinal mucormycosisBritish Journal of Surgery, 1991